More information: Lyndsey Flanagan et al, Steroid-free combination of 5-azacytidine and venetoclax for the treatment of ...
The US Food and Drug Administration approved 5-azacytidine for the treatment of MDS in 2004. The drug improves bone marrow function by freeing up the genes the body needs to make normal blood cells.
11mon
News Medical on MSNVenetoclax combo opens new treatment path for incurable multiple myelomaBy combining venetoclax and 5-azacytidine we've seen enhanced efficacy across a wide range of patient samples. It shows the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results